Navigation Links
Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor
Date:8/12/2014

LAWRENCE, Mass., Aug. 12, 2014 /PRNewswire/ -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide leader in the field of nephrology, will join the Company as Senior Medical Advisor and head the Company's Medical Advisory Board. 

Dr. Collins is a Professor of Medicine at the University of Minnesota.  He is the Director of the Chronic Research Disease Group, an interdisciplinary biomedical research group committed to the investigation of chronic illnesses to improve public health, and as part of this, served as the coordinating center for the United States Renal Data System (USRDS) and its Annual Data Report from 2000 through 2014.  Dr. Collins was presented the Distinguished Service Award by the National Kidney Foundation (NKF) in 2003, and served as the President of the NKF from 2006 through 2008.  He has over 200 clinical publications, and is an invited lecturer worldwide.  Dr. Collins continues his clinical practice with dialysis patients under his care as the Medical Director for the DaVita Coon Valley Dialysis Unit.  Dr. Collins has served as a member of the NxStage® Scientific Advisory Board for the last 4 years.

"I believe fresh approaches with innovative technologies are essential to address the long intractable problems we've seen with chronic dialysis therapy, particularly cardiovascular issues and low quality of life," said Collins. "The talented NxStage team has substantially advanced home dialysis therapies to date, and will continue to do so on a broader scale with future innovations.  It will be a pleasure to help advance the care of the dialysis population by advising NxStage on data-driven analytics and communications while leading a world-class team of medical advisors."

Dr. Collins will assume the leadership role from Dr. Alan Hull, who has headed the NxStage Medical Advisory Board since 2004.

"We have always actively sought the best scientific counsel in our ongoing mission to invent, improve and inspire," said Joe Turk, NxStage's President. "We thank Dr. Hull for all of his years of commitment, and we are delighted that Dr. Collins will now be collaborating so closely with NxStage going forward.  NxStage, and future patients for our life-changing technologies, will benefit from the ongoing contributions of Dr. Collins' tremendous knowledge and leadership skills."

About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:
Meredith D'Agostino
mdagostino@451marketing.com
516-884-7162

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO


'/>"/>
SOURCE NxStage Medical Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
2. HeartWare International Announces Appointment Of Katrin Leadley, M.D., As Chief Medical Officer
3. Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
4. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
5. LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer
6. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
7. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
8. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
11. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):